MiMedx Group inc (NASDAQ:MDXG) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
MiMedx Group inc (NASDAQ:MDXG) gained 1.82 Percent and closed its previous trading session at $3.35. The stock traded with the average Volume of 3.1 Million at the end of last session.
MiMedx Group inc (NASDAQ:MDXG) has the Market Capitalization of 441.9 Million. The Stock has its 52-week High of $18.25 and 52-Week Low of $ 3.01 and it touched its 52-week high on 01/29/18 and 52-Week Low on 07/10/18
The company reported its last earnings Actual EPS of $0.08/share. While, the analyst predicted that the company could provide an EPS of $0.08/share.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated MiMedx Group inc (NASDAQ:MDXG) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -33.15% where SMA50 and SMA200 are -49.04% and -66.82% respectively.
The company shows its Return on Assets (ROA) value of 18.6%. The Return on Equity (ROE) value stands at 25.6%. While it’s Return on Investment (ROI) value is 9.3%.
MiMedx Group inc (NASDAQ:MDXG) currently has a Weekly Volatility of 12.26% percent while its Monthly Volatility is at 10.69% percent. While talking about Performance of the Stock, MiMedx Group inc currently has a Weekly performance of -10.9%, monthly performance percentage is -43.6 percent, Quarterly performance is -51.73 percent, 6 months performance shows a percent value of -76.61% and Yearly Performance is -77.59 percent.
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.